Today's Peptide News — September 24, 2026

A UC Berkeley-led team gave semaglutide to 20-month-old female mice, roughly the equivalent of late middle age, and followed them for the rest of their lives. Median lifespan rose from 742 days in untreated controls to 834 days in treated animals, a gain of about three months. The drug cut food intake by around 24% and reduced body weight mainly by trimming fat mass.

Beyond lifespan, treated mice moved and explored more, had better motor coordination, muscle function, spatial memory, glucose control and insulin sensitivity. At the cellular level the authors report improved blood stem cell function, more hippocampal neurogenesis, less inflammation and senescence, better mitochondrial function and greater genomic stability.

The team also ran a matched 24% calorie-restriction arm. Both interventions shifted liver gene expression in similar directions, but semaglutide pushed exploratory drive, memory and glycemic control above baseline where calorie restriction only held them steady, and it did so without the hunger-driven metabolic rhythms seen with restriction. That suggests the GLP-1 receptor agonist is doing more than simply making the animals eat less.

The caveats are important: this was one sex, one species, and one lab's cohort. Whether any GLP-1 drug changes human aging trajectories would need long-term trials in older adults. For PeptideWiki, the natural angle is 'semaglutide as a calorie-restriction mimetic — and where it goes beyond one', tying the mouse data to the growing list of off-target benefits reported for GLP-1 drugs.

Researchers at the University of Geneva have traced part of the chronic infection problem in cystic fibrosis to a gap-junction protein, connexin 43. In healthy airways it switches on mainly during tissue repair, but in cystic fibrosis cells it stays abnormally active, scrambling cell orientation, degrading tissue organisation and creating adhesion sites that act as anchor points for pathogenic bacteria.

Using 3D cultures derived from human lung cells, the team blocked connexin 43 activity and restored normal cell orientation and spatial organisation, preventing the anchor points from forming. Short synthetic mimetic peptides already used to promote wound healing, and already in clinical trials in dermatology and oncology, drastically reduced bacterial colonisation of the airway cells.

The work, published in Communications Biology, is still preclinical and limited to in vitro models. Its appeal is that it targets the host barrier rather than the bacteria, which could complement antibiotics and CFTR modulators. A short PeptideWiki post could explain connexin mimetic peptides as a repurposing story: a wound-healing peptide class finding a second job in lung defence.

A target-trial emulation of 333,687 US veterans with type 2 diabetes, published in BMJ Medicine, compared GLP-1 receptor agonist users with people on sulfonylureas over three years. Continuous GLP-1 use was linked to an 18% lower risk of major adverse cardiovascular events, about four fewer heart attacks, strokes or deaths per 100 people.

The protection faded quickly when treatment stopped. About 26% of GLP-1 users quit entirely and another 23% had a gap of at least six months. Even a six-month interruption raised risk 4% to 8% relative to continuous use; one year off without restarting raised it 14%, and two years off raised it 22%. People who stopped before 18 months showed no significant benefit over sulfonylureas, and restarting restored only part of the benefit.

Senior author Ziyad Al-Aly frames it as metabolic whiplash: inflammation, blood pressure and cholesterol rebound along with weight. As an observational analysis in a mostly male veteran population it cannot prove causation. For PeptideWiki it is a strong hook for a post on GLP-1 adherence and what the evidence says about stopping these peptides.

A UCLA Health team analysed 565 studies on six popular unapproved peptides and secretagogues — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu — looking at musculoskeletal healing, tissue recovery and performance. Their conclusion, published in The American Journal of Sports Medicine, is that marketing claims have run well ahead of the science.

More than two-thirds of the studies were done only in animals, and the limited human work was generally of low quality. The authors flag safety signals, including an MK-677 trial halted over congestive heart failure risk, and warn that unregulated products may contain undisclosed or harmful substances.

The review lands as the FDA loosens compounding restrictions on several of these compounds, so it is timely reference material. A PeptideWiki post could summarise the evidence tier for each of the six compounds in plain language — animal-only, weak human data, or safety concern — and link out to each peptide's page.

Viking Therapeutics reported maintenance data on September 22 for VK2735, its injectable GLP-1/GIP dual agonist. In the 180-person study, adults with obesity first took weekly doses of 15 to 22.5 mg for 21 weeks and lost roughly 16% to 19% of body weight, versus about 0% on placebo.

Participants were then moved to less frequent dosing for 12 weeks. Those on every-other-week injections retained up to 97% of their weight loss, and those on monthly injections retained 82% to 90%, compared with 61% for people switched to placebo. Gastrointestinal side-effect rates during maintenance were similar to placebo, and discontinuations due to adverse events were 2% to 3%.

Investors reacted strongly, with shares jumping about 36% in a day. Less frequent maintenance dosing could matter for cost, adherence and tolerability as the obesity market moves from getting weight off to keeping it off.

At its Capital Markets Day in London on September 21, Novo Nordisk laid out strategic ambitions for 2030, including launching more than five multi-blockbuster products and reaching over 150 billion Danish kroner in risk-adjusted pipeline sales by 2035. The company aims to have at least five Phase 3 programmes in obesity and diabetes and at least five in other therapy areas.

The plan did not calm investors. Shares fell about 7% on the day amid worries about competition from Eli Lilly and others, and ahead of list-price cuts of roughly 50% for Wegovy and 35% for Ozempic scheduled for January 1, 2027. Management also signalled a larger appetite for deals, which lifted several smaller obesity biotechs.

An analysis of more than 92 million US adults with no documented diabetes or obesity diagnosis found that GLP-1 receptor agonist prescribing in this group rose 15-fold between 2021 and 2025, and the growth was uneven across demographic groups.

One finding stands out for safety: recipients were six times as likely as non-recipients to have a history of eating disorders (1.8% versus 0.3%). The data add to calls for tighter prescribing oversight as GLP-1 use spreads well beyond its approved indications.

Stanford researchers report in Nature Neuroscience that the forebrain and midbrain arise from one progenitor population, marked by the gene Otx2, while the hindbrain comes from a separate Gbx2-expressing population. The two do not overlap even at the earliest stages examined, and they have fundamentally different chromatin configurations.

The same two-origin pattern appears in chickens, zebrafish and acorn worms, suggesting that evolution fused two ancient nervous systems over more than 500 million years. Using this insight, the team made functional human hindbrain motor neurons from stem cells for the first time, a new tool for studying ALS, spinal muscular atrophy and the brainstem hunger circuits that GLP-1 drugs act on.

A systematic review and meta-analysis of 69 randomised trials involving 153,902 adults found that calcium, vitamin D, or the two combined had little to no meaningful effect on fractures, hip fractures or falls in most older people. Much of the evidence was rated moderate to high certainty.

The authors say the data do not support routine supplementation for this purpose and urge guideline bodies to re-evaluate. The findings may not apply to people with specific bone disorders or those on osteoporosis treatment, and an accompanying editorial points to balance and resistance training as better-supported ways to prevent falls.

Baylor College of Medicine researchers developed CS18, a small molecule that blocks the BRCT7/8 region of TopBP1, a hub protein that interacts with MYC regulators, mutant p53, PLK1 and CIP2A. Blocking it reduced several pro-survival pathways at once and increased cancer cell death across triple-negative breast, ovarian, lung and leukemia cell lines, with less toxicity to normal cells.

CS18 boosted the effect of PARP inhibitors and restored sensitivity to osimertinib in resistant lung cancer cells. It also slowed tumour growth in animal models without obvious toxicity. The work, published in Science Advances, is preclinical.